Q3 revenues increased by 18% to $27.4 million Adjusted EBITDA profitability of $1.0 million for Q3 Acquisition of ExoDx business from Bio-Techne Corporation Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the three and... Read More

Company to Host Conference Call with Live Q&A, November 12, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – November 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2025, after market close on Wednesday, November 12, 2025. Title: Mdxhealth Presents Third Quarter 2025 Financial... Read More

IRVINE, CA, and HERSTAL, BELGIUM – September 15, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the closing of the ExoDx business acquisition from Bio-Techne Corporation, which includes the ExoDx Prostate test. Acquisition of ExoDx Business On August 5, 2025, mdxhealth signed a definitive agreement to acquire Exosome Diagnostics,... Read More

Year-over-year Q2 revenues increased by 20% to $26.6 million Adjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growth and be accretive to adjusted EBITDA Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 5, 2025 (GlobeNewswire) –... Read More

IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of... Read More

Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31,... Read More

Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title: Mdxhealth Presents First Quarter 2025 Financial Results and... Read More

Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the... Read More

Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, February 26, 2025. Title: Mdxhealth Presents... Read More

IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for... Read More

MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36 th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City. Piper... Read More

Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for... Read More

MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 14, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30,... Read More

IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“ mdxhealth ” or the “ Company “), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“ Ordinary Shares ”) in a registered public offering (the “ Offering ”) at a price to the public of $2.00 per... Read More

IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“ mdxhealth ” or the “ Company ”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40.0 million of ordinary shares of the Company without nominal value (" Ordinary Shares ") in a registered public offering (the “ Offering ”). The Company also expects to grant the underwriters a... Read More

Year-over-year Q2 revenues increase by 32% to $22.2 million Year-over-year H1 revenues increase by 34% to 42.0 million Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the second quarter and half... Read More

MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and... Read More

IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a... Read More

IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary Q2 and half year 2024 revenues and cash. The Company expects to report Q2 and half year 2024 revenues of approximately $22.2 and $42.0 million, respectively, representing year-over-year growth of 32% and 34%, respectively, and representing sequential... Read More

IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024. William Blair 44 th Annual Growth Stock Conference Presentation: Wednesday, June 5, at 5:00pm ET Webcast:... Read More

Year-over-year Q1 revenues increase by 35% to $19.8 million Increasing 2024 revenue guidance to $83-85 million, previously $79-81 million\ Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the first... Read More

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive... Read More

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision... Read More

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 21, 2024 – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended... Read More